nach oben

Erschienen in:

12.01.2021 | Research Article

Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study

verfasst von: D-Y-L Chang-Chan, R. Ríos-Tamayo, M. Rodríguez Barranco, D. Redondo-Sánchez, Y. González, R. Marcos-Gragera, M. J. Sánchez

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Despite major advances, multiple myeloma remains an incurable disease. Epidemiological data from high-quality population-based registries are needed to understand the heterogeneous landscape of the disease.

Methods

Incidence, mortality and survival in multiple myeloma were comprehensively analyzed in the Girona and Granada population-based cancer registries, over a 23-year study (1994–2016), divided into three periods (1994–2001, 2002–2009 and 2010–2016). Joinpoint regression analysis was used to estimate the annual percentage change in incidence and mortality. Age-standardized net survival was calculated with the Pohar–Perme method.

Results

1957 myeloma patients were included in the study, with a median age of 72 years. Age-standardized incidence and mortality rates decreased over time in both sexes and both rates were higher in males. Five-year age-standardized net survival by period was 27.4% (1994–2001), 38.8% (2002–2009), and 47.4% (2010–2016). Survival improved for all age groups: 32.4%, 74.1% and 78.5% for patients aged 15–49; 27.5%, 44.6%, and 58.5% for those aged 50–69; finally, 24.8%, 25.5%, and 26.3% for the older group.

Conclusion

Incidence remained overall stable throughout the study, with only a small increase for men. Mortality was progressively decreasing in both sexes. Both incidence and mortality were higher in men. Age plays a critical role in survival, with impressive improvement in patients younger than 70 years, but only a minor benefit in those older than 70.

Nur mit Berechtigung zugänglich

Swerdlow SH, Campo E, Pileri SA, Lee N, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569.CrossRefPubMedPubMedCentral

Rajkumar SV, Dimopoulos MA, Palumbo A, Bladé J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5.CrossRefPubMed

Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R and Ferlay J, editors (2017) Cancer Incidence in Five Continents, Vol. XI (electronic version). Lyon: International Agency for Research on Cancer. Available from: http://ci5.iarc.fr, (Accessed 9 Dec 2017)

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñero M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53. https://doi.org/10.1002/ijc.31937.CrossRef

Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma. A systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221–7.CrossRef

Galceran J, Amejide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19(7):799–825. https://doi.org/10.1007/s12094-016-1607-9.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Ca Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.213590.CrossRefPubMed

Ludwig H, Novis S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the Globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020. https://doi.org/10.1634/theoncologist.2020-0141.CrossRefPubMedPubMedCentral

Ríos-Tamayo R, Sánchez D, Chang-Chan DY, Sánchez MJ. Epidemiology of multiple myeloma. In: Al-Anazi KA, editor. Update on multiple myeloma. London: Intech; 2018.

10.

De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15(1):23–34.CrossRef

11.

Ríos-Tamayo R, Sánchez MJ, Puerta JM, Sainz J, Chang-Chan DY, Rodríguez T, et al. Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. Cancer Epidemiol. 2015;39(5):693–9. https://doi.org/10.1016/j.canep.2015.08.002.CrossRefPubMed

12.

Villavicencio A, Solans M, Auñón-Sanz C, Roncero JM, Marcos-Gragera R. Population-based survival of lymphoid neoplasms: twenty years of epidemiological data in the Girona province. Spain Cancer Epidemiol. 2020. https://doi.org/10.1016/j.canep.2020.101841.CrossRefPubMed

13.

Ríos-Tamayo R, Sainz J, Martínez-López J, Puerta JM, Chang-Chan DY, Rodríguez T, et al. Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients. Am J Hematol. 2016;91(7):700–4. https://doi.org/10.1002/ajh.24389.CrossRefPubMed

14.

Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1(4):282–7. https://doi.org/10.1182/bloodadvances.2016002493.CrossRefPubMedPubMedCentral

15.

Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, et al. Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018;103(3):506–13. https://doi.org/10.3324/haematol.2017.178103.CrossRefPubMedPubMedCentral

16.

Andres M, Feller A, Arndt V, the NICER Working Group. Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013. Cancer Epidemiol. 2018;53(4):105–10. https://doi.org/10.1016/j.canep.2018.01.015.CrossRef

17.

Sneyd MJ, Cox B, Morison IM. Trends in myeloma incidence, mortality and survival in New Zealand (1985–2016). Cancer Epidemiol. 2019;60(6):55–9. https://doi.org/10.1016/j.canep.2019.03.006.CrossRefPubMed

18.

Solans M, Fàbrega A, Morea D, Auñon-Sanz C, Granada I, Roncero JM, et al. Population-based incidence of lymphoid neoplasms: twenty years of epidemiological data in the Girona province. Spain Cancer Epidemiol. 2019;58(2):8–11. https://doi.org/10.1016/j.canep.2018.11.001.CrossRefPubMed

19.

Bora K. Distribution of multiple myeloma in India: heterogeneity in incidence across age, sex and geography. Cancer Epidemiol. 2019;59(4):215–20. https://doi.org/10.1016/j.canep.2019.02.010.CrossRefPubMed

20.

Tsang M, Le M, Ghazawi FM, Cyr J, Alakel A, Rahme E, et al. Multiple myeloma epidemiology and patient geographic distribution in Canada: a population study. Cancer. 2019;125(14):2435–44. https://doi.org/10.1002/cncr.32128.CrossRefPubMed

21.

Latifi-Pupovci H, Selmonaj M, Ahmetah-Shala B, Dushi M, Grajqevci V. Incidence of haematological malignancies in Kosovo. A post “uranium war” concern. PLoS ONE. 2020;15:0232063. https://doi.org/10.1371/journal.pone.0232063.CrossRef

22.

Wang S, Xu L, Feng J, Liu Y, Liu L, Wang J, et al. Prevalence and Incidence of multiple myeloma in urban area in China: A national population-based analysis. Front Oncol. 2020;9:1513. https://doi.org/10.3389/fonc.2019.01513.CrossRefPubMedPubMedCentral

23.

Langseth ØO, Myklebust TÅ, Johannesen TB, Hjertner Ø, Waage A. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982–2017. Br J Haematol. 2020;191(3):418–517. https://doi.org/10.1111/bjh.16674.CrossRefPubMed

24.

Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:26. https://doi.org/10.1038/s41408-018-0065-8.CrossRefPubMedPubMedCentral

25.

Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–67. https://doi.org/10.1002/ajh.25791.CrossRef

26.

Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94. https://doi.org/10.1038/s41408-020-00359-2.CrossRefPubMedPubMedCentral

27.

Richardson PG, San Miguel J, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:109. https://doi.org/10.1038/s41408-018-0141-0.CrossRefPubMedPubMedCentral

28.

Mai EK, Haas EM, Lücke S, Löpprich M, Kunz C, Pritsch M, et al. A systematic classification of death causes in multiple myeloma. Blood Cancer J. 2018;8:30. https://doi.org/10.1038/s41408-018-0068-5.CrossRefPubMedPubMedCentral

29.

Mohty M, Cavo M, Fink L, Gonzalez-McQuire S, Leleu H, Mateos MV, et al. Understanding mortality in multiple myeloma: findings of a European retrospective chart review. Eur J Haematol. 2019;103(2):107–15. https://doi.org/10.1111/ejh.13264.CrossRefPubMedPubMedCentral

30.

Liu W, Liu J, Song Y, Wang X, Zhou M, Wang L, et al. Mortality of lymphoma and myeloma in China, 2004–2017: an observational study. J Hematol Oncol. 2019;12:22. https://doi.org/10.1186/s13045-019-0706-9.CrossRefPubMedPubMedCentral

31.

Castañeda-Avila MA, Ortiz-Ortiz KJ, Torres-Cintrón CR, Birmann BM, Epstein MM. Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987–2013. Int J Cancer. 2020;146(1):35–43. https://doi.org/10.1002/ijc.32232.CrossRefPubMed

32.

Ríos-Tamayo R, Sainz J, Puerta JM, Romero A, González PA, López P, et al. The role of diagnostic delay in multiple myeloma: “A delay paradox.” Haematologica. 2015;100(s1):510.

33.

Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW, et al. Time from first symptom onset to the final diagnosis of multiple myeloma (MM)-possible risks and future solutions: retrospective and prospective ‘Deutsche Studiengruppe MM’ (DSMM) and ‘European Myeloma Network? (EMN) analysis. Leuk Lymphoma. 2020;61(4):875–86. https://doi.org/10.1080/10428194.2019.1695051.CrossRefPubMed

34.

Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10:56. https://doi.org/10.1038/s41408-020-0323-4.CrossRefPubMedPubMedCentral

35.

Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica. 2018;103:e412. https://doi.org/10.3324/haematol.2017.183475.CrossRefPubMedPubMedCentral

36.

Turesson I, Bjorkholm M, Blimark CH, Kristinson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018;101(2):237–44. https://doi.org/10.1111/ejh.13083.CrossRef

37.

Howell D, Smith A, Appleton S, Bagguley T, Macleod U, Cook G, Patmore R, et al. Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study. Br J Haematol. 2017;177(1):67–71. https://doi.org/10.1111/bjh.14513.CrossRefPubMedPubMedCentral

38.

Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, et al. Characteristics of long-term survivors with multiple myeloma: a national cancer data base analysis. Cancer. 2019;125(20):3574–81. https://doi.org/10.1002/cncr.32357.CrossRefPubMed

39.

Weil C, Gelerstein S, Moser SS, Chodick G, Ben-David NB, Shalev V, et al. Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan. Leuk Res. 2019;85(10):106219. https://doi.org/10.1016/j.leukres.2019.106219.CrossRefPubMed

40.

Çiftçiler R, Göker H, Demiroglu H, Aksu S, Saynalp N, Haznedaroglu IC, et al. Evaluation of the survival outcomes of multiple myeloma patients according to their plasmacytoma presentation at diagnosis. Turk J Hematol. 2020;37(4):256–62. https://doi.org/10.4274/tjh.galenos.2019.2019.0061.CrossRef

41.

Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132–41. https://doi.org/10.1016/S0140-6736(19)32956-3.CrossRefPubMed

42.

Çiftçiler R, Göker H, Buyukasik Y, Saynalp N, Haznedaroglu IC, Aksu S, et al. Comparison of bortezomib-cyclophosphamide-dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients. Hematol Rep. 2020;12:8267. https://doi.org/10.4081/hr.2020.8267.CrossRefPubMedPubMedCentral

43.

Göker H, Çiftçiler R, Demiroglu H, Turgut M, Saynalp N, Haznedaroglu IC, et al. Predictive factors for stem cell mobilization failure in multiple myeloma patients: a single center experience. Transfus Apher Sci. 2020;59(1):102595. https://doi.org/10.1016/j.transci.2019.06.023.CrossRefPubMed

44.

Demiroglu H, Çiftçiler R, Buyukasik Y, Göker H. Prediction of stem cell mobilization failure in patients with Hodgkin and non-Hodgkin lymphoma. Turk J Hematol. 2020. https://doi.org/10.4274/tjh.galenos.2020.2020.0409.CrossRef

45.

Afshar N, English DR, Blakely T, Thusfield V, Farrugia H, Giles GG, et al. Differences in cancer survival by area-level socio-economic disadvantage: a population-based study using cancer registry data. PLoS ONE. 2020;15:e0228551. https://doi.org/10.1371/journal.pone.0228551.CrossRefPubMedPubMedCentral

Titel: Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study
verfasst von: D-Y-L Chang-Chan
R. Ríos-Tamayo
M. Rodríguez Barranco
D. Redondo-Sánchez
Y. González
R. Marcos-Gragera
M. J. Sánchez
Publikationsdatum: 12.01.2021
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 7/2021
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02541-1

Springer Medizin

Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study